<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598179</url>
  </required_header>
  <id_info>
    <org_study_id>JSPH-CART001</org_study_id>
    <nct_id>NCT03598179</nct_id>
  </id_info>
  <brief_title>XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects</brief_title>
  <official_title>A Single-center, Open Study Evaluating Efficacy and Safety of XLCART001（CD-19） Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital with Nanjing Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is a single arm, single-center, non-randomized clinical trial which is designed to
      evaluate the efficacy and safety of XLCART001 in treatment of relapsed/refractory/high-risk
      B-cell malignancy subjects
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>Overall response rate (ORR) = complete response (CR) rate + partial response (PR) rate, ORR will be assessed at weeks 12.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>6 months,1 year, 2 years</time_frame>
    <description>from the time of enrollment to death from any cause or the date of the last follow-up visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>12 weeks,6 months,1 year, 2 years</time_frame>
    <description>the time from enrollment to disease progression, death from any cause, or the date of the last follow-up visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event-free Survival</measure>
    <time_frame>12 weeks,6 months,1 year, 2 years</time_frame>
    <description>the time from enrollment to any events, or the date of the last follow-up visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>28 days</time_frame>
    <description>Non-haematological dose-limiting toxicities was any toxicity of grade 3 or higher occurring within 28 days of XLCART001 infusion judged possibly related to the treatment regimen.The following toxicities were not considered dose limiting toxicities: tumor lysis syndrome, abnormal electrolytes responding to supplementation, hypoalbuminemia, liver dysfunction resolving to ≤grade 2 within 14 days, transient (&lt;72 hours) grade 4 hepatic enzyme abnormality, and grade 3 or 4 fever or neutropenic fever.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of CAR-T cells</measure>
    <time_frame>Day 1, Day 4, Day 7, Day 10, Day 14, Day 21, Day 28, 8 weeks, 12 weeks, 6 months, 1 years, 2 years</time_frame>
    <description>The number of CAR-T cells detected by flow cytometry and copy number of CAR-T cells tested by polymerase chain reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of CAR-T cells</measure>
    <time_frame>Day 1, Day 4, Day 7, Day 10, Day 14, Day 21, Day 28, 8 weeks, 12 weeks, 6 months, 1 years, 2 years</time_frame>
    <description>The duration of CAR-T cells detected by flow cytometry and copy number of CAR-T cells tested by polymerase chain reaction</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Leukemia, B-cell</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>chimeric antigen receptor T cells</intervention_name>
    <description>Dose CAR+ cells/kg B-cell lymphoma 4×10^6 Acute lymphocytic leukemia 2×10^6 Chronic lymphocytic leukemia 10×10^6</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years, male and female,

          -  Confirmed as CD19-positive B cell lymphoma/leukemia by immunohistochemistry or flow
             cytometry

          -  No effective treatment

          -  Patients must have a measurable or evaluable disease at the time of enrollment.

          -  Adequate organ system function including:

               -  ALT/AST &lt; 3 upper limit of normal; Total Bilirubin &lt; 2.5 upper limit of normal

               -  Creatinine &lt; 2 upper limit of normal

               -  Oxygen saturation ≥ 95%

               -  Left ventricular ejection fraction ≥ 40%

               -  Number of neutrophil ≥ 0.75×10^9/L, number of platelet ≥ 50×10^9/L

          -  At least 4 weeks from receiving previous treatment (radiotherapy, chemotherapy,
             monoclonal antibody therapy or other treatments)

          -  No contraindications of peripheral blood apheresis

          -  Female subjects in childbearing age, their serum or urine pregnancy test must be
             negative. All patients must agree to take effective contraceptive measures during the
             trial measures

          -  ECOG score 0-2, expected survival ≥ 12 weeks

        Exclusion Criteria:

          -  Women who are pregnant or lactating. Patients have breeding intent in 12 months or
             cannot take effective contraceptive measures during the trial measures

          -  Uncontrollable active infection within four week. Prophylactic antibiotic, antiviral
             and antifungal treatment is permissible. Active hepatitis B or hepatitis C virus
             infection, as well as acquired, congenital immune deficiency diseases, including but
             not limited to HIV-infected persons

          -  Subjects with any autoimmune disease or any immune deficiency disease

          -  Have a history of allergy to antibodies or cellular products

          -  Participated in any other clinical trial within four weeks

          -  Used of systemic steroids within four weeks (using inhaled steroids or ≤ 20mg/d
             prednison are exceptions)

          -  Have mental diseases

          -  Have history of drug addiction

          -  The investigators believe that any increase in the risk of the subject or interference
             with the results of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital</name>
      <address>
        <city>Nanjin</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 27, 2018</study_first_submitted>
  <study_first_submitted_qc>July 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>August 5, 2019</last_update_submitted>
  <last_update_submitted_qc>August 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital with Nanjing Medical University</investigator_affiliation>
    <investigator_full_name>JianYong Li</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

